Publications
2024
Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters
Neary, M., Gallardo-Toledo, E., Sharp, J., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (n.d.). Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters. Viruses, 16(12). doi:10.3390/v16121838
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
Tatham, L., Kipar, A., Sharp, J., Kijak, E., Herriott, J., Neary, M., . . . Owen, A. (2024). Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.. Microbiology spectrum, 12(8), e0391623. doi:10.1128/spectrum.03916-23
Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.
Kiiza, D., Rostami-Hochaghan, D., Alhassan, Y., Seden, K., Reynolds, H., Kaboggoza, J. P., . . . Lamorde, M. (2024). Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.. The Journal of antimicrobial chemotherapy, dkae232. doi:10.1093/jac/dkae232
The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19
Sequential Infection with Influenza A Virus Followed by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Leads to More Severe Disease and Encephalitis in a Mouse Model of COVID-19.
Clark, J. J., Penrice-Randal, R., Sharma, P., Dong, X., Pennington, S. H., Marriott, A. E., . . . Stewart, J. P. (2024). Sequential Infection with Influenza A Virus Followed by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Leads to More Severe Disease and Encephalitis in a Mouse Model of COVID-19.. Viruses, 16(6), 863. doi:10.3390/v16060863
Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models.
Sotrovimab Lacks Efficacy in Treatment of Syrian Golden Hamsters Infected With SARS-CoV-2 BQ.1.1
Tatham, L., Sharp, J., Neary, M., Herriott, J., Kijak, E., Gallardo-Toledo, E., . . . Owen, A. (2024). Sotrovimab Lacks Efficacy in Treatment of Syrian Golden Hamsters Infected With SARS-CoV-2 BQ.1.1. Poster session presented at the meeting of The 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024). Denver, US.
2023
Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters.
Box, H. J., Sharp, J., Pennington, S. H., Kijak, E., Tatham, L., Caygill, C. H., . . . Owen, A. (2023). Lack of antiviral activity of probenecid in vitro and in Syrian golden hamsters.. The Journal of antimicrobial chemotherapy, dkad362. doi:10.1093/jac/dkad362
Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters.
Gallardo-Toledo, E., Neary, M., Sharp, J., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters.. Viruses, 15(11), 2161. doi:10.3390/v15112161
Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters
Neary, M., Sharp, J., Gallardo-Toledo, E., Herriott, J., Kijak, E., Bramwell, C., . . . Owen, A. (2023). Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters. VIRUSES-BASEL, 15(8). doi:10.3390/v15081744
Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research
Neary, M., Arshad, U., Tatham, L., Pertinez, H., Box, H., Rajoli, R. K. R., . . . Owen, A. (2023). Quantitation of tizoxanide in multiple matrices to support cell culture, animal and human research. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1228. doi:10.1016/j.jchromb.2023.123823
Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.
Curley, P., Hobson, J. J., Liptrott, N. J., Makarov, E., Al-Khouja, A., Tatham, L., . . . Owen, A. (2023). Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.. Pharmaceutics, 15(7), 1835. doi:10.3390/pharmaceutics15071835
Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2
Gaynor, K. U. U., Vaysburd, M., Harman, M. A. J., Albecka, A., Jeffrey, P., Beswick, P., . . . James, L. C. C. (2023). Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2. NATURE COMMUNICATIONS, 14(1). doi:10.1038/s41467-023-39158-1
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., . . . Sampaziotis, F. (2023). FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. NATURE, 615(7950), 134-+. doi:10.1038/s41586-022-05594-0
2022
Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays.
2021
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection
Hobson, J. J., Savage, A. C., Dwyer, A., Unsworth, C., Massam, J., Arshad, U., . . . Rannard, S. (n.d.). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. Nanoscale. doi:10.1039/d1nr00309g
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis
Rajoli, R. K. R., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2021). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 2078-2088. doi:10.1111/bcp.14619
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection
Hobson, J., Savage, A., Dwyer, A., Unsworth, C., Arshad, U., Pertinez, H., . . . Rannard, S. (2021). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. doi:10.26434/chemrxiv.13587035
Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection
Hobson, J., Savage, A., Dwyer, A., Unsworth, C., Arshad, U., Pertinez, H., . . . Rannard, S. (2021). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. doi:10.26434/chemrxiv.13587035.v1
2020
Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19
Clark, J., Penrice-Randal, R., Sharma, P., Kipar, A., Dong, X., Pennington, S., . . . Stewart, J. (2020). Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19. doi:10.1101/2020.10.13.334532
Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909
Dose Prediction for Repurposing Nitazoxanide in SARS-CoV-2 Treatment or Chemoprophylaxis
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.
Rajoli, R. K., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2020). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.. medRxiv : the preprint server for health sciences. doi:10.1101/2020.05.01.20087130
Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K. R., Curley, P., . . . Owen, A. (2020). Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics. doi:10.1101/2020.04.16.20068379
2018
Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro
Gurjar, R., Chan, C. Y. S., Curley, P., Sharp, J., Chiong, J., Rannard, S., . . . Owen, A. (2018). Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. MOLECULAR PHARMACEUTICS, 15(11), 4835-4842. doi:10.1021/acs.molpharmaceut.8b00482
Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis
Box, H., Negri, C., Livermore, J., Whalley, S., Johnson, A., McEntee, L., . . . Hope, W. (2018). Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(5). doi:10.1128/AAC.02516-17
Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.
Negri, C. E., Johnson, A., McEntee, L., Box, H., Whalley, S., Schwartz, J. A., . . . Hope, W. W. (2018). Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus.. The Journal of infectious diseases, 217(7), 1118-1127. doi:10.1093/infdis/jix479
Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease
Nixon, G. L., McEntee, L., Johnson, A., Farrington, N., Whalley, S., Livermore, J., . . . Hope, W. (2018). Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. Antimicrobial Agents and Chemotherapy, 62(4), e01909-e01917. doi:10.1128/aac.01909-17
Preclinical evaluation of reduced dose darunavir/ritonavir nanoparticle formulation.
Box, H., Sharp, J., Neary, M. G., Moss, D., Tatham, L., Savage, A., . . . Owen, A. (n.d.). Preclinical evaluation of reduced dose darunavir/ritonavir nanoparticle formulation.. In CROI. Boston, MA, USA.
2017
Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.
Hope, W. W., McEntee, L., Livermore, J., Whalley, S., Johnson, A., Farrington, N., . . . Rex, J. H. (n.d.). Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease.. mBio, 8(4). doi:10.1128/mbio.01157-17
Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.
Lestner, J., McEntee, L., Johnson, A., Livermore, J., Whalley, S., Schwartz, J., . . . Hope, W. (2017). Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.. Antimicrobial agents and chemotherapy, 61(06), 11 pages. doi:10.1128/aac.00090-17
Haloprogin
Ramos-Martín, V., & Hope, W. (2017). Haloprogin. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 2933-2935). doi:10.1201/9781315152110
2016
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., . . . Birch, M. (2016). F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 113(45), 12809-12814. doi:10.1073/pnas.1608304113
Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates
Ramos-Martin, V., Johnson, A., Livermore, J., McEntee, L., Goodwin, J., Whalley, S., . . . Hope, W. W. (2016). Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. Journal of Antimicrobial Chemotherapy, 71(4), 992-1002. doi:10.1093/jac/dkv451
Pharmacodynamics of Isavuconazole in a Dynamic <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis
Box, H., Livermore, J., Johnson, A., McEntee, L., Felton, T. W., Whalley, S., . . . Hope, W. W. (2016). Pharmacodynamics of Isavuconazole in a Dynamic <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(1), 278-287. doi:10.1128/AAC.01364-15
2014
An invertebrate model to evaluate virulence in <i>Aspergillus fumigatus</i>: The role of azole resistance
Gomez-Lopez, A., Forastiero, A., Cendejas-Bueno, E., Gregson, L., Mellado, E., Howard, S. J., . . . Cuenca-Estrella, M. (2014). An invertebrate model to evaluate virulence in <i>Aspergillus fumigatus</i>: The role of azole resistance. MEDICAL MYCOLOGY, 52(3), 311-319. doi:10.1093/mmy/myt022
Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days
Livermore, J., Howard, S. J., Sharp, A. D., Goodwin, J., Gregson, L., Felton, T., . . . Hope, W. (2014). Efficacy of an Abbreviated Induction Regimen of Amphotericin B Deoxycholate for Cryptococcal Meningoencephalitis: 3 Days of Therapy Is Equivalent to 14 Days. mBio, 5(1). doi:10.1128/mBio.00725-13
2013
Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i>
Felton, T. W., Goodwin, J., O'Connor, L., Sharp, A., Gregson, L., Livermore, J., . . . Hope, W. W. (2013). Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(12), 5811-5819. doi:10.1128/AAC.00867-13
Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients
O'Connor, L., Livermore, J., Sharp, A. D., Goodwin, J., Gregson, L., Howard, S. J., . . . Hope, W. W. (2013). Pharmacodynamics of Liposomal Amphotericin B and Flucytosine for Cryptococcal Meningoencephalitis: Safe and Effective Regimens for Immunocompromised Patients. JOURNAL OF INFECTIOUS DISEASES, 208(2), 351-361. doi:10.1093/infdis/jit164
Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and <i>In Vitro</i> Susceptibility Breakpoints
Sudan, A., Livermore, J., Howard, S. J., Al-Nakeeb, Z., Sharp, A., Goodwin, J., . . . Hope, W. W. (2013). Pharmacokinetics and Pharmacodynamics of Fluconazole for Cryptococcal Meningoencephalitis: Implications for Antifungal Therapy and <i>In Vitro</i> Susceptibility Breakpoints. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(6), 2793-2800. doi:10.1128/AAC.00216-13
Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.
Sudan, A., Livermore, J., Howard, S. J., Al-Nakeeb, Z., Sharp, A., Goodwin, J., . . . Hope, W. W. (2013). Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.. Antimicrobial Agents and Chemotherapy, 57(6), 2793-2800.
Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental <i>Candida</i> Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection
Livermore, J. L., Felton, T. W., Abbott, J., Sharp, A., Goodwin, J., Gregson, L., . . . Hope, W. W. (2013). Pharmacokinetics and Pharmacodynamics of Anidulafungin for Experimental <i>Candida</i> Endophthalmitis: Insights into the Utility of Echinocandins for Treatment of a Potentially Sight-Threatening Infection. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 57(1), 281-288. doi:10.1128/AAC.01387-12
2012
The Aspergillus fumigatus dihydroxyacid dehydratase Ilv3A/IlvC is required for full virulence.
Oliver, J. D., Kaye, S. J., Tuckwell, D., Johns, A. E., Macdonald, D. A., Livermore, J., . . . Bromley, M. J. (2012). The Aspergillus fumigatus dihydroxyacid dehydratase Ilv3A/IlvC is required for full virulence.. PloS one, 7(9), e43559. doi:10.1371/journal.pone.0043559
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections
Livermore, J., & Hope, W. (2012). Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 8(6), 759-765. doi:10.1517/17425255.2012.683859
Anidulafungin for Neonatal Hematogenous <i>Candida</i> Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach
Warn, P. A., Livermore, J., Howard, S., Felton, T. W., Sharp, A., Gregson, L., . . . Hope, W. W. (2012). Anidulafungin for Neonatal Hematogenous <i>Candida</i> Meningoencephalitis: Identification of Candidate Regimens for Humans Using a Translational Pharmacological Approach. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 708-714. doi:10.1128/AAC.05826-11
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
Livermore, J., & Hope, W. (2012). Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.. Expert Opin Drug Metab Toxicol, 8(6), 759-765. Retrieved from http://informahealthcare.com/doi/abs/10.1517/17425255.2012.683859
2011
Pharmacodynamics of Echinocandins against <i>Candida glabrata</i>: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts
Howard, S. J., Livermore, J., Sharp, A., Goodwin, J., Gregson, L., Alastruey-Izquierdo, A., . . . Hope, W. W. (2011). Pharmacodynamics of Echinocandins against <i>Candida glabrata</i>: Requirement for Dosage Escalation To Achieve Maximal Antifungal Activity in Neutropenic Hosts. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(10), 4880-4887. doi:10.1128/AAC.00621-11
Disseminated Candidiasis Caused by <i>Candida albicans</i> with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin
Slater, J. L., Howard, S. J., Sharp, A., Goodwin, J., Gregson, L. M., Alastruey-Izquierdo, A., . . . Hope, W. W. (2011). Disseminated Candidiasis Caused by <i>Candida albicans</i> with Amino Acid Substitutions in Fks1 at Position Ser645 Cannot Be Successfully Treated with Micafungin. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(7), 3075-3083. doi:10.1128/AAC.01686-10
Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy
Howard, S. J., Lestner, J. M., Sharp, A., Gregson, L., Goodwin, J., Slater, J., . . . Hope, W. W. (2011). Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal Therapy. JOURNAL OF INFECTIOUS DISEASES, 203(9), 1324-1332. doi:10.1093/infdis/jir023
Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice.
Slater, J. L., Gregson, L., Denning, D. W., & Warn, P. A. (2011). Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice.. Medical mycology, 49 Suppl 1, S107-S113. doi:10.3109/13693786.2010.523852